Skip to main content
. 2021 Feb 10;95(5):e02214-20. doi: 10.1128/JVI.02214-20

TABLE 1.

Baseline characteristics of PLWH upon study entry

Characteristic Value for patient:
1 2 3 4 5 6 7 8 9 10
Age (yrs) 50 63 33 57 53 33 38 61 26 52
CD4+ nadir (cells/mm3) 392 365 479 272 250 186 50 633 234
CD4+ (cells/mm3) 1,029 504 522 970 773 700 603 502 774 417
CD4+/CD8+ 1.07 1.04 0.8 0.7 0.99 1.2 0.4 0.6 0.8 0.4
HIV-1 RNA (copies/ml) <37 <37 <37 <37 <37 <37 <37 <37 <37 <37
ART duration (months) 41 185 48 324 43 72 72 270 12 12
ARTa RPV, TAF, FTC RPV, DTG DTG, ABC, 3TC DTG, ABC, 3TC RPV, DTG DRV, COBI, FTC, TAF EVG, COBI, FTC, TAF DRV, RTV, 3TC DTG, ABC, 3TC EVG, COBI, FTC, TAF
a

RPV, rilpivirine; TAF, tenofovir alafenamide; FTC, emtricitabine; DTG, dolutegravir; ABC, abacavir; 3TC, lamivudine; DRV, darunavir; COBI, cobicistat; EVG, elvitegravir.